Cell & Gene Therapy Manufacturing

Belkins
The race towards commercialisation of cell and gene products has already begun. Where technology innovations are pathing the way towards the development of these products, challenges surrounding scale up and closed system processing highlight areas that need our focus so that cell and gene therapy products can be produced on an industrial scale The Cell and Gene Therapy Manufacturing Forum is the only conference that is 100% dedicated to focusing on development of manufacturing processes for these products. With presentations on improving cost efficiency, innovative strategies for commercialisation as well as closed system processing, optimised manufacturing scheduling and maintaining GMP compliance, this forum is one that is not to be missed!

Related News

ALLERGAN TO ACQUIRE ACELITY’S REGENERATIVE MEDICINE UNIT LIFECELL FOR $2.9BN

Allergan | December 22, 2016

news image

US-based drugmaker Allergan has signed an agreement to acquire Acelity’s regenerative medicine unit LifeCell in a deal valued at $2.9bn.The acquisition will combine LifeCell's business, including its portfolio of dermal matrix products with Allergan's portfolio of medical aesthetics, breast implants and tissue expanders....

Read More

RESIDUE ON CELL PHONES USED TO CREATE 'PORTRAITS' OF USERS

Pharama | November 15, 2016

news image

Along with forensic evidence in criminal cases, this process can be applied to many situations, said study lead investigator Pieter Dorrestein, a professor in UCSD's School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences....

Read More

GREINER BIO-ONE NORTH AMERICA, INC. LAUNCHES NEW INNOVATIVE CELLDISC™ PRODUCT FOR MASS CELL CULTURE

PharmiWeb Solutions | February 10, 2017

news image

Greiner Bio-One North America, Inc. has added a new and innovative product to the already robust portfolio for cell culture that is specifically used for mass cell culture. CELLdisc™ is a new multilayer device covering a range of cell culture surfaces from 1,000 cm2 up to 1 square meter. The innovative ergonomic design of CELLdisc™ provides a versatile system for the propagation of adherent mammalian cells from research scale to industrial batches....

Read More

DENOVO BIOPHARMA PLANS TO LAUNCH A GLOBAL PHASE III TRIAL OF DB102 (ENZASTAURIN) IN DIFFUSE LARGE B-CELL LYMPHOMA

Denovo Biopharma | February 16, 2017

news image

Denovo Biopharma LLC, a leading company in precision medicine announces the plan to initiate a biomarker driven global phase 3 clinical trial for its lead drug DB102 as a first line therapy for diffuse large B-cell lymphoma (DLBCL) patients this year....

Read More
news image

ALLERGAN TO ACQUIRE ACELITY’S REGENERATIVE MEDICINE UNIT LIFECELL FOR $2.9BN

Allergan | December 22, 2016

US-based drugmaker Allergan has signed an agreement to acquire Acelity’s regenerative medicine unit LifeCell in a deal valued at $2.9bn.The acquisition will combine LifeCell's business, including its portfolio of dermal matrix products with Allergan's portfolio of medical aesthetics, breast implants and tissue expanders....

Read More
news image

RESIDUE ON CELL PHONES USED TO CREATE 'PORTRAITS' OF USERS

Pharama | November 15, 2016

Along with forensic evidence in criminal cases, this process can be applied to many situations, said study lead investigator Pieter Dorrestein, a professor in UCSD's School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences....

Read More
news image

GREINER BIO-ONE NORTH AMERICA, INC. LAUNCHES NEW INNOVATIVE CELLDISC™ PRODUCT FOR MASS CELL CULTURE

PharmiWeb Solutions | February 10, 2017

Greiner Bio-One North America, Inc. has added a new and innovative product to the already robust portfolio for cell culture that is specifically used for mass cell culture. CELLdisc™ is a new multilayer device covering a range of cell culture surfaces from 1,000 cm2 up to 1 square meter. The innovative ergonomic design of CELLdisc™ provides a versatile system for the propagation of adherent mammalian cells from research scale to industrial batches....

Read More
news image

DENOVO BIOPHARMA PLANS TO LAUNCH A GLOBAL PHASE III TRIAL OF DB102 (ENZASTAURIN) IN DIFFUSE LARGE B-CELL LYMPHOMA

Denovo Biopharma | February 16, 2017

Denovo Biopharma LLC, a leading company in precision medicine announces the plan to initiate a biomarker driven global phase 3 clinical trial for its lead drug DB102 as a first line therapy for diffuse large B-cell lymphoma (DLBCL) patients this year....

Read More